Effect of red cell transfusions on future kidney transplantation

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 5, 2013, Pages 852-860

  Obrador, Gregorio T ^a   Macdougall, Iain C ^b  

^a UNIVERSIDAD PANAMERICANA   (Mexico)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HLA ANTIBODY; HLA ANTIGEN; LYMPHOCYTE ANTIBODY;

ANEMIA; BLEEDING; BLOOD; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); ERYTHROCYTE TRANSFUSION; GRAFT SURVIVAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IRON THERAPY; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SENSITIZATION; COMPLICATION; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANEMIA; ERYTHROCYTE TRANSFUSION; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877737953     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00020112     Document Type: Review

References (74)

1. Opelz G, Terasaki PI: Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 299: 799-803, 1978
2. Cecka JM: The transfusion effect. Clin Transpl 287-301, 1987
3. Opelz G, Terasaki PI: Poor kidney-transplant survival in recipients with frozen-blood transfusions or no transfusions. Lancet 2: 696-698, 1974
4. Feduska NJ, Vincenti F, Amend WJ Jr, Duca R, Cochrum K, Salvatierra O Jr: Do blood transfusions enhance the possibility of a compatible transplant? Transplantation 27: 35-38, 1979
5. Corry RJ, West JC, Hunsicker LG, Schanbacher BA, Lachenbruch PA: Effect of timing of administration and quantity of blood transfusion on cadaver renal transplant survival. Transplantation 30: 425-428, 1980
6. Frisk B, Brynger H, Wedel N, Sandberg L: Blood transfusion in cadaveric renal transplantation-a prospective study. Scand J Urol Nephrol Suppl 64: 100-105, 1981
7. Chapman JR, Ting A, Fisher M, Carter NP, Morris PJ: Failure of platelet transfusion to improve human renal allograft survival. Transplantation 41: 468-473, 1986
8. Opelz G, Terasaki PI: Importance of preoperative (not peroper-ative) transfusions for cadaver kidney transplants. Transplantation 31: 106-108, 1981
9. Fuller TC, Delmonico FL, Cosimi B, Huggins CE, King M, Russell PS: Impact of blood transfusion on renal transplantation. Ann Surg 187: 211-218, 1978
10. Opelz G: Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation 40: 240-243, 1985
11. Cecka JM, Cicciarelli J, Mickey MR, Terasaki PI: Blood transfusions and HLA matching-an either/or situation in cadaveric renal transplantation. Transplantation 45: 81-86, 1988
12. Ahmed Z, Terasaki PI: Effect of transfusions. Clin Transpl 305-312, 1991
13. Terasaki PI, McClelland JD, Yuge J, Cecka JM, Gjertson DW, Takemoto S, Cho YW: Advances in kidney transplantation: 1985-1995. Clin Transpl 485: 487-501, 1995
14. Carpenter CB: Blood transfusion effects in kidney transplantation. Yale J Biol Med 63: 435-443, 1990
15. Salvatierra O Jr, Melzer J, Potter D, Garovoy M, Vincenti F, Amend WJ, Husing R, Hopper S, Feduska NJ: Aseven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation 40: 654-659, 1985
16. Middleton D, Martin J, Douglas J, McClelland M: Transfusion of one HLA-DR antigen-matched blood to potential recipients of a renal allograft. Transplantation 58: 845-848, 1994
17. Scornik JC, Salomon DR, Howard RJ, Pfaff WW: Prevention of transfusion-induced broad sensitization in renal transplant candidates. Transplantation 47: 617-620, 1989
18. Ibrahim S, Jakobs F, Kittur D, Hess A, Linsley PS, Sanfilippo F, Baldwin WM 3rd: CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Blood 88: 4594-4600, 1996
19. Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, Largiader F, Lange H, Vujaklija-Stipanovic K, Alvarez-Grande J, Schott W, Hoyer J, Schnuelle P, Descoeudres C, Ruder H, Wujciak T, Schwarz V: Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63: 964-967, 1997
20. Vella JP, O'Neill D, Atkins N, Donohoe JF, Walshe JJ: Sensitization to humanleukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 13: 2027-2032, 1998
21. Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB: Effects of recombinant human eryth-ropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38: 12-18, 1990
22. Deierhoi MH, Barger BO, Hudson SL, Shroyer TW, Diethelm AG: The effect of erythropoietin and blood transfusions on highly sensitized patients on a single cadaver renal allograft waiting list. Transplantation 53: 363-368, 1992
23. Fehrman-Ekholm I, Sumitran-Karuppan S: Antibodies in alloim-munized uraemic patients treated with recombinant erythro-poietin. Transpl Int 7[Suppl 1]: S290-S293, 1994
24. U.S. Renal Data System;: USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
25. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators;: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085- 2098, 2006
26. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators;: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. NEnglJMed355: 2071-2084, 2006
27. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators;: A trial of darbepoetin alfa in type 2 diabetes and chronickidney disease. N Engl J Med 361: 2019-2032, 2009
28. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators;: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146-1155, 2010
29. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
30. Rosner MH, Bolton WK: The mortality risk associated with higher hemoglobin: Is the therapy to blame? Kidney Int 74: 695-697, 2008
31. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
32. Opelz G, Graver B, Mickey MR, Terasaki PI: Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 32: 177-183, 1981
33. Reed A, Pirsch J, Armbrust MJ, Burlingham WJ, Knechtle SJ, D'Alessandro AM, Sollinger HW, Lorentzen D, Kalayoglu M, Belzer FO: Multivariate analysis of donor-specific versus random transfusion protocols in haploidentical living-related transplants. Transplantation 51: 382-384, 1991
34. Vanrenterghem Y, Waer M, Roels L, Coosemans W, Christaens MR, Opelz G; Leuven Collaborative Group for Transplantation;: A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. Transpl Int 7 [Suppl 1]: S243-S246, 1994
35. Christiaans MH, van Hooff JP, Nieman F, van den Berg-Loonen EM: HLA-DR matched transfusions: development of donor-specific T- and B-cell antibodies and renal allograft outcome. Transplantation 67: 1029-1035, 1999
36. Pfaff WW, Howard RJ, Scornik JC, Day C, Renderer J, Scott J, Fennel RS, Peterson JC, Salomon DR, Patton PR: Incidental and purposeful random donor blood transfusion. Sensitization and transplantation. Transplantation 47: 130-133, 1989
37. Sanfilippo F, Vaughn WK, Bollinger RR, Spees EK: Comparative effects of pregnancy, transfusion, and prior graft rejection on sensitization and renal transplant results. Transplantation 34: 360-366, 1982
38. U.S. Renal Data System;: USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
39. Williamson LM: Leucocyte depletion of the blood supply-how will patients benefit? Br J Haematol 110: 256-272, 2000
40. Vamvakas EC: WBC-containing allogeneic blood transfusion and mortality: A meta-analysis of randomized controlled trials. Transfusion 43: 963-973, 2003
41. Goodnough LT: The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 40: 1522-1527, 2000
42. Vamvakas EC, Blajchman MA: Universal WBC reduction: The case for and against. Transfusion 41: 691-712, 2001
43. Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT: Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 41: 997- 1000, 2001
44. Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kalish LA, Stowell CP: A prospective, randomized clinical trial of universal WBC reduction. Transfusion 42: 1114-1122, 2002
45. Ratko TA, Cummings JP, Oberman HA, Crookston KP, DeChristopher PJ, Eastlund DT, Godwin JE, Sacher RA, Yawn DH, Matuszewski KA; University Health System Consortium;: Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 41: 1310-1319, 2001
46. Cleemput I, Leys M, Ramaekers D, Bonneux L: Balancing evidence and public opinion in health technology assessments: The case of leukoreduction. Int J Technol Assess Health Care 22: 403-407, 2006
47. Bassuni WY, Blajchman MA, Al-Moshary MA: Why implement universal leukoreduction? Hematol Oncol Stem Cell Ther 1: 106-123, 2008
48. Scornik JC, Ireland JE, Howard RJ, Fennell RS 3rd, Pfaff WW: Role of regular and leukocyte-freeblood transfusions in the generation of broad sensitization. Transplantation 38: 594-598, 1984
49. Sanfilippo FP, Bollinger RR, MacQueen JM, Brooks BJ, Koepke JA: A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allo-graft recipients. Transfusion 25: 116-119, 1985
50. Karpinski M, Pochinco D, Dembinski I, Laidlaw W, Zacharias J, Nickerson P: Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 15: 818-824, 2004
51. Everett ET, Kao KJ, Scornik JC: Class I HLA molecules on human erythrocytes. Quantitation and transfusion effects. Transplantation 44: 123-129, 1987
52. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K: Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 270: 1339-1343, 1993
53. Oniscu GC, Brown H, Forsythe JL: Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 16: 1859-1865, 2005
54. Agarwal R: Individualizing decision-making-resurrecting the doctor-patient relationship in the anemia debate. Clin J Am Soc Nephrol 5: 1340-1346, 2010
55. Terasaki PI, Ozawa M: Predicting kidney graft failure by HLA antibodies: A prospectivetrial. Am J Transplant 4:438-443, 2004
56. Cecka JM, Cho L: Sensitization. Clin Transpl 365-373, 1988
57. Opelz G; Collaborative Transplant Study;: Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365: 1570-1576, 2005
58. Terasaki PI, Ozawa M: Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial. Transplantation 80: 1194-1197, 2005
59. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21: 1398-1406, 2010
60. Cecka JM: Calculated PRA (CPRA): The new measure of sensiti-zation for transplant candidates. Am J Transplant 10: 26-29, 2010
61. Cecka JM: Transplantation: Desensitization and transplantation for sensitized patients? Nat Rev Nephrol 7: 682-683, 2011
62. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2: 758-760, 2002
63. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immu-noglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 15: 3256-3262, 2004
64. Marfo K, Lu A, Ling M, Akalin E: Desensitization protocols and their outcome. Clin J Am Soc Nephrol 6: 922-936, 2011
65. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL: Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365: 318-326, 2011
66. Blumberg JM, Gritsch H, Veale JL: Kidney paired donation: Advancements and future directions. Curr Opin Organ Transplant 16: 380-384, 2011
67. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: A multicen-ter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340: 409-417, 1999
68. Kansagara D, Dyer EAW, Englander H, Freeman M, Kagen D: Treatment of anemia in patients with heart disease: a systematic review. VA-ESP Project #05-225, Washington, DC, Department of Veterans Affairs, 2011
69. Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, Duguid J, Knowles SM, Poole G, Williamson LM; British Committee for Standards in Haematology, Blood Transfusion Task Force;: Guidelines for the clinical use of red cell transfusions. Br J Haematol 113: 24-31, 2001
70. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine;: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157, 2007
71. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG; American College of Chest Physicians: Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 670S-707S, 2008
72. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society;: ACC/ AHA 2005 GuidelineUpdate for theDiagnosis andManagement of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235, 2005
73. Heart Failure Society of America;: Nonpharmacologic management and health care maintenance in patients with chronic heart failure. J Card Fail 12: e29-e37, 2006
74. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG);: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Societyof Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442, 2008